Jean Holloway Sells 10,000 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 10,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $46.18, for a total value of $461,800.00. Following the sale, the senior vice president owned 169,169 shares in the company, valued at $7,812,224.42. The trade was a 5.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Artivion Trading Down 4.3%

NYSE:AORT opened at $45.57 on Friday. The firm has a market capitalization of $2.16 billion, a P/E ratio of -108.49 and a beta of 1.65. The business has a 50 day simple moving average of $42.64 and a 200 day simple moving average of $36.03. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.04.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.Artivion’s revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Equities research analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently added to or reduced their stakes in AORT. Entropy Technologies LP acquired a new stake in shares of Artivion during the third quarter worth $220,000. Kennedy Capital Management LLC increased its stake in Artivion by 19.0% in the 3rd quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock worth $18,536,000 after purchasing an additional 70,030 shares in the last quarter. Sei Investments Co. raised its holdings in Artivion by 13.4% during the 3rd quarter. Sei Investments Co. now owns 59,343 shares of the company’s stock worth $2,513,000 after buying an additional 7,016 shares during the period. UBS Group AG raised its holdings in Artivion by 2.1% during the 3rd quarter. UBS Group AG now owns 204,069 shares of the company’s stock worth $8,640,000 after buying an additional 4,110 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in Artivion by 88.2% during the third quarter. BNP Paribas Financial Markets now owns 108,161 shares of the company’s stock valued at $4,580,000 after buying an additional 50,675 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Citizens Jmp raised their price target on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Needham & Company LLC raised their target price on Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Canaccord Genuity Group boosted their price target on Artivion from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Stifel Nicolaus increased their price target on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Finally, LADENBURG THALM/SH SH lowered Artivion from a “buy” rating to a “neutral” rating and raised their price target for the company from $32.00 to $38.80 in a report on Wednesday, August 13th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Artivion has an average rating of “Moderate Buy” and a consensus price target of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.